土茯苓复方制剂对氧嗪酸钾致高尿酸血症改善作用的研究

Effect of Smilax Glabra Formulated Preparation on the Hyperuricemia Induced by Potassium Oxonate

采用氧嗪酸钾灌胃建立高尿酸血症大鼠模型,并考察一种土茯苓复方制剂的降尿酸效果。结果显示,大鼠按照1.5 g/(kg·d)剂量连续灌胃氧嗪酸钾30 d可以建立高尿酸血症大鼠模型,在第15 d和第30d检测时,模型动物的血清尿酸水平与正常对照组比较均有显著性差异,并且血清尿素氮和肌酐未见病理性改变;采用土茯苓复方制剂样品连续灌胃30 d(在第15 d和第30 d检测),样品大、小剂量均可以显著降低模型动物的血清尿酸、尿素氮含量;而样品大剂量可以显著降低模型动物的血清肌酐水平。采用该土茯苓复方制剂样品连续灌胃后均可以不同程度地降低相应模型动物的血清尿酸、尿素氮和肌酐的含量。因此,该土茯苓复方制剂对氧嗪酸钾致高尿酸血症有一定的改善作用。

The rat model of hyperuricemia was established by oral gavage with potassium oxonate, and the effect of a Smilax Glabra prescription on the hyperuricemia was studied. The rat model of hyperuricemia was established in accordance with 1.5 g/（kg？d） continuous intragastric dose by potassium oxonate for 30 d. When tested at the 15th and 30th d, serum uric acids in the model were significantly different to the normal control group, urea nitrogen and creatinine in the serum had no pathological change. After continuously oral gavage for 30 d with Smilax Glabra prescription （15th and 30th d tests）, the serum uric acid and urea nitrogen were reduced in the corresponding model with different doses and the creatinine was significantly reduced with high doses. Therefore the Smilax Glabra prescription has a certain effect on potassium oxonate-induced hyperuricemia.